Cost-effectiveness of enfuvirtide for treatment-experienced patients with HIV in Italy

John Hornberger, Jesse Green, Neil Wintfeld, Matthias Cavassini, Jürgen Rockstroh, Giovanni Giuliani, Claudio De Carli, Adriano Lazzarin

Research output: Contribution to journalArticlepeer-review


Background: Enfuvirtide (ENF) plus an optimized background (OB) antiretroviral regimen delays virological failure (VF), reduces HIV-1 viral load, and increases CD4 count compared with OB only in pretreated patients. Purpose: To forecast long-term outcomes, costs, and cost-effectiveness of ENF+OB vs. OB in the Italian health care system. Method: A Markov model was developed and clinical trial results on viral suppression and CD4 count were linked with data from HAART-era studies of the risk of AIDS-defining events (ADEs) and death. Resource data were obtained from Italian sources on direct medical costs. Cost-effectiveness was computed as the incremental cost per quality-adjusted life year (QALY) saved. Results: Patients receiving ENF+OB were projected to experience a mean time to virological failure of 1.0 years vs. 0.5 years for OB and mean time to immunological failure of 3.1 years vs. 1.3 years for OB. Life expectancy and QALYs were greater for ENF+OB than OB by 1.8 and 1.5 years, respectively. Total lifetime medical cost was €126,487 for ENF+OB and €84,416 for OB, a difference of €42,071 due to the cost of ENF itself (€18,400) and the medical costs associated with additional life expectancy (€23,671). The incremental cost-effectiveness of ENF+OB was €23,721 per life year (€28,669 per QALY). Conclusion: ENF+OB is predicted to increase life expectancy at a cost per life year that is comparable to many well-accepted therapies in Europe.

Original languageEnglish
Pages (from-to)92-102
Number of pages11
JournalHIV Clinical Trials
Issue number2
Publication statusPublished - Mar 2005


  • Cost-benefit analysis
  • Enfuvirtide
  • HIV

ASJC Scopus subject areas

  • Virology
  • Immunology


Dive into the research topics of 'Cost-effectiveness of enfuvirtide for treatment-experienced patients with HIV in Italy'. Together they form a unique fingerprint.

Cite this